251 related articles for article (PubMed ID: 8573100)
1. Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site.
Schülein R; Liebenhoff U; Müller H; Birnbaumer M; Rosenthal W
Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):611-6. PubMed ID: 8573100
[TBL] [Abstract][Full Text] [Related]
2. A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells.
Schülein R; Hermosilla R; Oksche A; Dehe M; Wiesner B; Krause G; Rosenthal W
Mol Pharmacol; 1998 Sep; 54(3):525-35. PubMed ID: 9730911
[TBL] [Abstract][Full Text] [Related]
3. An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system.
Birnbaumer M; Gilbert S; Rosenthal W
Mol Endocrinol; 1994 Jul; 8(7):886-94. PubMed ID: 7984150
[TBL] [Abstract][Full Text] [Related]
4. The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues.
Schülein R; Zühlke K; Oksche A; Hermosilla R; Furkert J; Rosenthal W
FEBS Lett; 2000 Jan; 466(1):101-6. PubMed ID: 10648821
[TBL] [Abstract][Full Text] [Related]
5. Palmitoylation of luteinizing hormone/human choriogonadotropin receptors in transfected cells. Abolition of palmitoylation by mutation of Cys-621 and Cys-622 residues in the cytoplasmic tail increases ligand-induced internalization of the receptor.
Kawate N; Menon KM
J Biol Chem; 1994 Dec; 269(48):30651-8. PubMed ID: 7982985
[TBL] [Abstract][Full Text] [Related]
6. Processing and ligand-induced modifications of the V2 vasopressin receptor.
Sadeghi HM; Innamorati G; Esqueda E; Birnbaumer M
Adv Exp Med Biol; 1998; 449():339-46. PubMed ID: 10026823
[TBL] [Abstract][Full Text] [Related]
7. Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1/2 activation.
Charest PG; Bouvier M
J Biol Chem; 2003 Oct; 278(42):41541-51. PubMed ID: 12900404
[TBL] [Abstract][Full Text] [Related]
8. Molecular aspects of vasopressin receptor function.
Schöneberg T; Kostenis E; Liu J; Gudermann T; Wess J
Adv Exp Med Biol; 1998; 449():347-58. PubMed ID: 10026824
[TBL] [Abstract][Full Text] [Related]
9. Palmitoylation of the V2 vasopressin receptor.
Sadeghi HM; Innamorati G; Dagarag M; Birnbaumer M
Mol Pharmacol; 1997 Jul; 52(1):21-9. PubMed ID: 9224808
[TBL] [Abstract][Full Text] [Related]
10. A serine cluster prevents recycling of the V2 vasopressin receptor.
Innamorati G; Sadeghi HM; Tran NT; Birnbaumer M
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2222-6. PubMed ID: 9482866
[TBL] [Abstract][Full Text] [Related]
11. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide.
Schoneberg T; Yun J; Wenkert D; Wess J
EMBO J; 1996 Mar; 15(6):1283-91. PubMed ID: 8635461
[TBL] [Abstract][Full Text] [Related]
12. Single amino acid substitutions and deletions that alter the G protein coupling properties of the V2 vasopressin receptor identified in yeast by receptor random mutagenesis.
Erlenbach I; Kostenis E; Schmidt C; Serradeil-Le Gal C; Raufaste D; Dumont ME; Pausch MH; Wess J
J Biol Chem; 2001 Aug; 276(31):29382-92. PubMed ID: 11375990
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements for V2 vasopressin receptor proteolytic cleavage.
Kojro E; Postina R; Gilbert S; Bender F; Krause G; Fahrenholz F
Eur J Biochem; 1999 Dec; 266(2):538-48. PubMed ID: 10561596
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
Oksche A; Schülein R; Rutz C; Liebenhoff U; Dickson J; Müller H; Birnbaumer M; Rosenthal W
Mol Pharmacol; 1996 Oct; 50(4):820-8. PubMed ID: 8863826
[TBL] [Abstract][Full Text] [Related]
15. Polarized expression of the vasopressin V2 receptor in Madin-Darby canine kidney cells.
Andersen-Beckh B; Dehe M; Schülein R; Wiesner B; Rutz C; Liebenhoff U; Rosenthal W; Oksche A
Kidney Int; 1999 Aug; 56(2):517-27. PubMed ID: 10432391
[TBL] [Abstract][Full Text] [Related]
16. Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase.
Rosenthal W; Antaramian A; Gilbert S; Birnbaumer M
J Biol Chem; 1993 Jun; 268(18):13030-3. PubMed ID: 8514744
[TBL] [Abstract][Full Text] [Related]
17. Mutations of the alpha 2A-adrenergic receptor that eliminate detectable palmitoylation do not perturb receptor-G-protein coupling.
Kennedy ME; Limbird LE
J Biol Chem; 1993 Apr; 268(11):8003-11. PubMed ID: 8385131
[TBL] [Abstract][Full Text] [Related]
18. The role of palmitoylation of the guanine nucleotide binding protein G11 alpha in defining interaction with the plasma membrane.
McCallum JF; Wise A; Grassie MA; Magee AI; Guzzi F; Parenti M; Milligan G
Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):1021-7. PubMed ID: 7575398
[TBL] [Abstract][Full Text] [Related]
19. Monensin-resistant LLC-PK1 cell mutants are affected in recycling of the adenylate cyclase-stimulating vasopressin V2-receptor.
Jans DA; Jans P; Luzius H; Fahrenholz F
Mol Cell Endocrinol; 1991 Oct; 81(1-3):165-74. PubMed ID: 1797584
[TBL] [Abstract][Full Text] [Related]
20. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.
Sugimoto T; Saito M; Mochizuki S; Watanabe Y; Hashimoto S; Kawashima H
J Biol Chem; 1994 Oct; 269(43):27088-92. PubMed ID: 7929452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
